By Mackenzie Tatananni

Vivek Ramaswamy sold more than $22 million worth of Roivant Sciences stock in three separate transactions last week, according to a filing with the U.S. Securities and Exchange Commission.

Ramaswamy founded Roivant Sciences in 2014 and served as CEO until 2021. He has no formal role with the company today and is labeled a 10% owner in SEC filings.

A Form 4 filed with the agency last week shows Ramaswamy sold 1,195,000 shares for $12.50 each on Sept. 3. This was followed by the sale of 194,933 shares for $12.92 each on Sept. 4. On Sept. 5, Ramaswamy sold an additional 385,816 shares at $12.96 apiece.

The total came to 1,775,749 shares of common stock that were sold for an average price of $12.79 each, or $22.7 million. Since Ramaswamy's final sale on Sept. 5, shares have gained 10%.

Ramaswamy has spent his time in politics since leaving Roivant. In 2024, he entered the presidential race, running as the youngest Republican candidate in a presidential primary. Ramaswamy ultimately withdrew and endorsed Donald Trump.

Hours after Trump took office on Jan. 20, Ramaswamy announced that he was backing out of the Department of Government Efficiency, a temporary advisory body he was expected to oversee alongside Tesla CEO Elon Musk.

The following month, Ramaswamy launched a gubernatorial campaign in his home state of Ohio. Fellow Republican Mike DeWine, the current governor, is set to leave the role in 2027.

Ramaswamy's campaign didn't respond to a request for comment from Barron's regarding the latest sale.

Following the transactions, Vivek owned 35,508,359 common shares, which are currently valued at $504 million. He indirectly owns an additional 13,357,857 shares through his spouse.

In August, Roivant posted fiscal first-quarter revenue of $2.2 billion, marking a decline from $8 billion in the previous quarter and below the $7.3 billion analysts anticipated. The biotech's quarterly net loss also came in wider than expected.

Still, shares are up 20% this year, buoyed by positive analyst ratings and investor optimism around Roivant's approach to drug development. The iShares Biotechnology exchange-traded fund, which includes Roivant among its holdings, has gained 8.9% by comparison.

Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

September 14, 2025 04:00 ET (08:00 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.